Growing tiny tumours in the lab could help treat cancer

ALMOST half a century after Richard Nixon declared war on cancer, there has been plenty of progress. But there is still no cure.

One reason is that “cancer” is an umbrella term that covers many different diseases. Although the fundamental mechanism is always the same—the uncontrolled proliferation of cells—the details vary enormously. Leukaemia is not the same as colon cancer. Even within a particular type of cancer, one patient’s disease will differ from another’s. Different mutations, for instance, will affect different genes within a tumour. The result is that cancer can be frustratingly difficult to treat.

Medicine, though, is getting better at accounting for these differences. In a paper just published in Nature Medicine, a team led by Meritxell Huch, a biologist at the Gurdon Institute, a cancer-research centre at the University of Cambridge, describes a technique that could, one day, help doctors design bespoke treatments for their patients, tailored to the precise characteristics of the cancers they are suffering from.

Dr Huch and her colleagues work with “organoids”, tiny replicas of full-sized organs that can be grown in the lab. The ability to build organ-like structures outside a living body, from retinas to kidneys and even brain tissue, holds a great deal of promise for medical research. But Dr Huch’s twist was to grow not organs, but the tumours that afflict them.

She and her team took cancerous cells from eight patients suffering from liver cancer. That is the fifth most frequent cancer in men around the world and the eighth most frequent in women. But its high mortality rate makes it the second most common cause of cancer deaths worldwide, behind only lung cancer. By immersing the cells in a specially developed culture medium designed to promote the survival of cancerous cells but not healthy ones, the researchers were able to persuade their samples to grow into tiny “tumouroids” about 0.5mm across.

Cancerous cells can already be cultured in test tubes, where they are available for poking and prodding by researchers. But, says Dr Huch, when researchers extract such tissue they often bring healthy cells along with it. That can complicate genetic analysis of the tumours, by mixing healthy DNA with the mutated sort. Because tumouroids contain only cancerous cells, analysing them should be easier.

A more significant benefit is that tumouroids replicate the structure of the tumours from which they are derived in a way that ordinary cell cultures do not. Cells in a living organism are often not symmetrical. The cells that make the intestines, for instance, need to know which side faces into the intestine and which side faces the rest of the body. That, in turn, means different genes are expressed in different parts of a cell. In a conventional cell culture, much of this structure is lost. But Dr Huch’s tumouroids preserve it, making them a much more faithful reproduction of the cancer from which they are derived.

Having copies of a tumour in a dish makes it easier to cDr Huch and her colleagues work with “organoids”, tiny replicas of full-sized organs that can be grown in the lab. The ability to build organ-like structures outside a living body, from retinas to kidneys and even brain tissue, holds a great deal of promise for medical research. But Dr Huch’s twist was to grow not organs, but the tumours that afflict them.

She and her team took cancerous cells from eight patients suffering from liver cancer. That is the fifth most frequent cancer in men around the world and the eighth most frequent in women. But its high mortality rate makes it the second most common cause of cancer deaths worldwide, behind only lung cancer. By immersing the cells in a specially developed culture medium designed to promote the survival of cancerous cells but not healthy ones, the researchers were able to persuade their samples to grow into tiny “tumouroids” about 0.5mm across.

Cancerous cells can already be cultured in test tubes, where they are available for poking and prodding by researchers. But, says Dr Huch, when researchers extract such tissue they often bring healthy cells along with it. That can complicate genetic analysis of the tumours, by mixing healthy DNA with the mutated sort. Because tumouroids contain only cancerous cells, analysing them should be easier.

A more significant benefit is that tumouroids replicate the structure of the tumours from which they are derived in a way that ordinary cell cultures do not. Cells in a living organism are often not symmetrical. The cells that make the intestines, for instance, need to know which side faces into the intestine and which side faces the rest of the body. That, in turn, means different genes are expressed in different parts of a cell. In a conventional cell culture, much of this structure is lost. But Dr Huch’s tumouroids preserve it, making them a much more faithful reproduction of the cancer from which they are derived.

Having copies of a tumour in a dish makes it easier to conduct experiments on them. By comparing the genomes of their tumouroids to those of healthy tissue, the team discovered unusually high levels of activity among some genes in the tumour cells. Nineteen of the 30 most over-active genes were already associated with a poor prognosis, but 11 were new genes for which such a link had not been suspected. They also used the tumouroids to test 29 sorts of anti-cancer drugs, some of which are still in development. For one, an inhibitor of a type of protein vital for tumour growth, the researchers have managed to publish the first evidence suggesting that it might indeed be effective.

The ability to grow accurate replicas of real tumours should help the hunt for better cancer drugs more generally. Compared with treatments for other diseases, many cancer drugs fail to make it past even the early stages of clinical trials, partly because of the difficulty of producing accurate models of the disease on which to do preliminary testing. Dr Huch hopes her tumouroids might have direct clinical applications, too. The goal, she says, would be to take a patient with liver cancer, grow copies of his tumour in a lab, and then test several different drug candidates at once to find the most effective. Because tumouroids faithfully replicate the cancers from which they are derived, a drug that works in the test tube should work in the patient as well. As any general will tell you, knowing your enemy is half the battle.

 

https://www.economist.com

Latest News

E-Health Project To Solve Drug shortages In Hospitals

June 23, 2018

Minister of Health, Nutrition and Indigenous Medicine Dr. Rajitha Senarathna...

Presidential Commission of Inquiry Into SriLankan Airlines: In Flight Duty Free Scam Exposed

June 23, 2018

A former employee of Phoenix Duty Free Services Marlon Ferreira...

Sandya to complain to CID

June 23, 2018

Sandya Ekneligoda was due to complain to the CID this...

Chandimal out of third Test, appeal against suspension dismissed

June 23, 2018

Sri Lanka captain Dinesh Chandimal will miss the day-night Test...

Connect with Us

fb twitter youtube g ins in

Most viewed in Last week

Pump and Dump Captains of Sri Lanka

June 17, 2018

Lanka News Web has over and over again highlighted that...

India observes National Dengu Day with the Power of Papaya Leaves but still where are we..?

June 20, 2018

Dr Sanath Hettige is the first Westeren Medical Researcher and...

UNESCO to be asked to remove Sinharaja from world heritages list

June 16, 2018

UNESCO will be asked to remove Sinharaja forest from the...

‘Not only a second tier, we have even developed a third tier leadership’ – PM Ranil!

June 18, 2018

‘The only second tier leader the UNP had was Sajith...